Qure AI vs Rayscape (2026)
Two comprehensive chest imaging platforms built for settings where a radiologist may not read the film at all. Qure holds the broadest regulatory footprint in chest radiography, nine products across radiography and computed tomography, with published device dossiers and deployments in screening programmes across several countries. Rayscape is smaller with the more interesting single piece of evidence: independent evaluation in a tuberculosis screening context, which tests the product under exactly the conditions that break imaging AI, plus longitudinal comparison against a patient's prior scans. Both offer on premise deployment, which matters where images cannot leave the country. Do not compare them on findings counts, which are counted differently and mean little. Compare them on performance for the findings your population actually presents with, at your prevalence.
- The regulatory footprint across chest radiography is the broadest in the market, spanning nine products across radiography and computed tomography with published device dossiers behind them.
- It is deployed where radiologist capacity is thinnest, including public health screening programmes, so the product has been proven under the conditions that break most imaging AI.
- On premise installation is supported and stated, which removes the data transfer question rather than governing it.
- Independent evaluation in a tuberculosis screening context is a harder test than a retrospective reader study, and it is the strongest single evidence point on either record.
- Longitudinal comparison across a patient's prior scans is built in, so change over time is visible rather than each study being read in isolation.
- Both on premise and cloud integration are offered, and the findings breadth on chest radiography is substantial.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Qure AI and Rayscape are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Qure AI | Rayscape |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2016 | 2019 |
| Headquarters | Mumbai, India | Timisoara, Romania |
| Website | qure.ai | rayscape.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Qure AI its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Rayscape, Qure AI grades higher on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Rayscape its top capability grade on AI Centrality. Set against Qure AI, Rayscape grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Qure AI or Rayscape?
On the axes where the AI Health Index separates them, Qure AI grades higher on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and Security Certifications and Trust Center, and Rayscape grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Neither leads on the greater share of scored axes, so the decision turns on which constraint is binding rather than on an overall winner.
Where do Qure AI and Rayscape differ most?
The widest separation the AI Health Index records between Qure AI and Rayscape is on FDA and Regulatory Status, where Qure AI grades A and Rayscape grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Qure AI and Rayscape grade the same?
The AI Health Index grades Qure AI and Rayscape the same on several axes, including AI Centrality, Autonomy and Oversight Model and AI Liability and Recourse. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The headline findings counts these vendors publish are not comparable, because each counts differently and per finding performance varies enormously within any such list; ask both for performance on the specific findings that matter in your population.
Prevalence is the other uncontrolled variable and it is decisive here: a model validated in a high tuberculosis burden setting produces very different positive predictive values in a low prevalence one, and neither publishes performance stratified that way. Neither holds a located security attestation or trust centre, and neither publishes pricing.